PharmGen Science, Inc. (KRX:004720)
South Korea
· Delayed Price · Currency is KRW 3,990.00
-40.00 (-0.99%)
At close: May 9, 2025, 3:30 PM KST
PharmGen Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 2,791 | 6,089 | 70,060 | 32,466 | 9,222 | Upgrade
|
| Depreciation & Amortization | 4,636 | 4,247 | 3,371 | 3,142 | 2,963 | Upgrade
|
| Loss (Gain) From Sale of Assets | 16.83 | -46.35 | -1.94 | 11.49 | 29.13 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 228.3 | 133.08 | 799.9 | 53.75 | Upgrade
|
| Loss (Gain) From Sale of Investments | 3,061 | -51.6 | -9.77 | -1.11 | 1,085 | Upgrade
|
| Loss (Gain) on Equity Investments | 4,916 | 2,539 | -87,213 | -46,633 | -14,508 | Upgrade
|
| Stock-Based Compensation | - | - | - | 4,359 | 1,671 | Upgrade
|
| Provision & Write-off of Bad Debts | 195.85 | -125.07 | -289.72 | 5.11 | 1,243 | Upgrade
|
| Other Operating Activities | 950.05 | -907.05 | 25,467 | 9,532 | 5,866 | Upgrade
|
| Change in Accounts Receivable | -3,878 | -7,454 | -7,901 | 1,433 | -3,480 | Upgrade
|
| Change in Inventory | -11,132 | 186.91 | -5,675 | 1,195 | -2,639 | Upgrade
|
| Change in Accounts Payable | 1,753 | -70.57 | 433.75 | 24.39 | 398.27 | Upgrade
|
| Change in Other Net Operating Assets | -925.88 | 804.17 | 340.48 | 1,450 | 771.63 | Upgrade
|
| Operating Cash Flow | 2,384 | 5,439 | -1,286 | 7,784 | 2,676 | Upgrade
|
| Operating Cash Flow Growth | -56.16% | - | - | 190.93% | 6.03% | Upgrade
|
| Capital Expenditures | -918.7 | -2,266 | -9,922 | -30,750 | -4,339 | Upgrade
|
| Sale of Property, Plant & Equipment | 28.28 | 80 | 190.25 | 46.58 | 5.3 | Upgrade
|
| Sale (Purchase) of Intangibles | -1,865 | -985.79 | -2,034 | -3,260 | -582.75 | Upgrade
|
| Investment in Securities | 1,500 | 6,490 | -3,498 | 1,501 | -550 | Upgrade
|
| Other Investing Activities | 365.88 | -58.67 | -20.38 | 2,077 | -2,254 | Upgrade
|
| Investing Cash Flow | -889.45 | 3,260 | -15,284 | -30,385 | -7,721 | Upgrade
|
| Short-Term Debt Issued | - | - | 389.68 | 1,169 | - | Upgrade
|
| Long-Term Debt Issued | - | 11,200 | 33,300 | 49,779 | 20,500 | Upgrade
|
| Total Debt Issued | - | 11,200 | 33,690 | 50,948 | 20,500 | Upgrade
|
| Short-Term Debt Repaid | - | - | -2,338 | - | - | Upgrade
|
| Long-Term Debt Repaid | -751.26 | -2,633 | -30,880 | -20,428 | -983.48 | Upgrade
|
| Total Debt Repaid | -751.26 | -2,633 | -33,218 | -20,428 | -983.48 | Upgrade
|
| Net Debt Issued (Repaid) | -751.26 | 8,567 | 471.8 | 30,521 | 19,517 | Upgrade
|
| Other Financing Activities | 267.31 | 284.59 | 1,797 | -180.05 | 51.18 | Upgrade
|
| Financing Cash Flow | -483.95 | 8,852 | 2,269 | 30,340 | 19,568 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | 0 | - | - | 0 | Upgrade
|
| Net Cash Flow | 1,011 | 17,551 | -14,302 | 7,739 | 14,523 | Upgrade
|
| Free Cash Flow | 1,466 | 3,173 | -11,208 | -22,966 | -1,664 | Upgrade
|
| Free Cash Flow Growth | -53.81% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 0.86% | 1.90% | -7.43% | -20.90% | -1.72% | Upgrade
|
| Free Cash Flow Per Share | 67.29 | 152.58 | -519.12 | -1234.84 | -110.74 | Upgrade
|
| Cash Interest Paid | 1,544 | 2,112 | 1,718 | 1,112 | 297.81 | Upgrade
|
| Cash Income Tax Paid | 131.67 | 2,124 | 52.99 | 866.9 | 209.36 | Upgrade
|
| Levered Free Cash Flow | -7,432 | -6,644 | -8,116 | -23,020 | -6,110 | Upgrade
|
| Unlevered Free Cash Flow | -4,834 | -3,979 | -5,922 | -21,944 | -5,929 | Upgrade
|
| Change in Net Working Capital | 13,328 | 10,678 | 1,970 | -7,651 | 4,450 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.